Striatal and extrastriatal dopamine D 2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: A positron emission tomography study with [ 11C]raclopride and [ 11C]FLB457

Psychopharmacology

Volumn 222, Issue 1, 2012, Pages 165-172

  Takahata, Keisuke ^a,b   Ito, Hiroshi ^a   Takano, Harumasa ^a   Arakawa, Ryosuke ^a   Fujiwara, Hironobu ^a   Kimura, Yasuyuki ^a   Kodaka, Fumitoshi ^a   Sasaki, Takeshi ^a   Nogami, Tsuyoshi ^a   Suzuki, Masayuki ^a   Nagashima, Tomohisa ^a   Shimada, Hitoshi ^a   Kato, Motoichiro ^b   Mimura, Masaru ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Aripiprazole; Dopamine D 2 receptor; Occupancy; Partial agonist

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; RACLOPRIDE C 11; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTERIOR CINGULATE; ARTICLE; BINDING AFFINITY; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; EXTRASTRIATE BODY AREA; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; MESENCEPHALON; NORMAL HUMAN; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; RISK FACTOR; TEMPORAL CORTEX; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CARBON RADIOISOTOPES; CORPUS STRIATUM; HUMANS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; QUINOLONES; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; YOUNG ADULT;

EID: 84862809670     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2633-5     Document Type: Article

References (44)

1. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T (2007) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2receptor occupancy in patients with schizophrenia. Psychopharmacology 197:229-235
2. Arakawa R, Ito H, Okumura M, Takano A, Takahashi H, Takano H, Okubo Y, Suhara T (2010) Extrastriatal dopamine D2 receptor occupancy in olanzapine-treated patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 260:345-350
3. Bhattacharjee J, El-Sayeh HGG (2008) Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews: CD006617
4. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C, Kerwin RW, Pilowsky LS (1999) In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPECT) study. Br J Psychiatry 175:231-238
5. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5-14 (Pubitemid 36164419)
6. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med 38:1614-1623 (Pubitemid 27443965)
7. Burris KD, Molski T, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca F, Molinoff P (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389 (Pubitemid 34680462)
8. Davies MA, Sheffler DJ, Roth BL (2006) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10:317-336 (Pubitemid 40128915)
9. Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS (2003) Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19:1205-1214 (Pubitemid 36918256)
10. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11 C]raclopride. Arch Gen Psychiatry 47:213-219
11. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
12. Farde L, Hall H, Pauli S, Halldin C (1995) Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20:200-208
13. Fox PT, Mintun MA, Reiman EM, Raichle ME (1988) Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb Blood Flow Metab 8:642-653
14. Gründer G, Landvogt C, Vernaleken I, Buchholz H-G, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P (2006) The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31:1027-1035
15. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I (2008) Brain and plasmapharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988-995
16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279-287 (Pubitemid 28018717)
17. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256 (Pubitemid 24372813)
18. Hall H, Farde L, Halldin C, Hurd Y, Pauli S (1996) Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I] epidepride. Synapse 23:115-123
19. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18:941-950
20. Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L (2001) Error Analysis for quantification of [11C]FLB 457 binding to extrastriatal D2 dopamine receptors in the human brain.Neuroimage 13:531-539
21. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T (2008) Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage 39:555-565 (Pubitemid 350117640)
22. Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12:667-675
23. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476 (Pubitemid 26113309)
24. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293 (Pubitemid 29077120)
25. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520 (Pubitemid 30191189)
26. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae S-A, Gonzales R, Kim J-H, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]Fallypride. Neuropsychopharmacology 33:3111-3125
27. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30:2283-2289 (Pubitemid 41643981)
28. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001
29. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
30. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42-52
31. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627 (Pubitemid 29189265)
32. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
33. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235 (Pubitemid 23091497)
34. Ohmori T, Miura S, Yamashita I, Koyama T, Yu M, Yagi G, Murasaki M, Kudo Y, Sakai T, Saito M, Watanabe M, Nakane M (2006) Long-term study to examine the efficacy and safety of aripiprazole for schizophrenia - extended study from a late phase II study. Jpn J Clin Psychopharmacol 9:453-474
35. Olsson H, Farde L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data. Neuroimage 14:936-945 (Pubitemid 32929894)
36. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491
37. Sudo Y, Suhara T, Inoue M, Ito H, Suzuki K, Saijo T, Halldin C, Farde L (2001) Reproducibility of [11C]FLB 457 binding in extrastriatal regions. Nucl Med Commun 22:1215-1221
38. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 2:73-82
39. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30 (Pubitemid 34044401)
40. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7:19-26 (Pubitemid 38523803)
41. Talvik M, Nordström A, Nyberg S (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [11C] raclopride and [11C] FLB 457. Am J Psychiatry 158:926-930
42. Watson C, Newport D, Casey M (1996) A single scatter simulation technique for scatter correction in 3D PET. In: Grangeat P, Amans J-L (eds) Three-dimensional image reconstruction in radiology and nuclear medicine. Kluwer Academic, Dordrecht, pp 255-268
43. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Mazière B, Paillère-Martinot ML (2001) Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508
44. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259